Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Femasys Inc. is a U.S.-based biopharmaceutical and medical device company focused on women’s health, with an emphasis on reproductive and gynecologic care. The company operates primarily in the medical devices and biopharmaceutical development industries, developing both commercial diagnostic products and investigational therapeutic technologies intended to address unmet needs in fertility care and contraception.
The company’s primary revenue-generating activities come from a portfolio of FDA-cleared, physician-used diagnostic and procedural devices, while its long-term value strategy centers on advancing proprietary drug-device combination products through clinical development. Femasys Inc. was founded in 2004 and evolved from an early-stage medical device developer into a publicly traded company, listing on Nasdaq in 2021. Its strategic positioning is focused on minimally invasive, office-based solutions for women’s reproductive health, an area that has historically seen limited innovation.
Business Operations
Femasys Inc. operates through a single reporting structure with two core business areas: Commercial Women’s Health Devices and Development-Stage Therapeutics and Drug-Device Combinations. Commercial revenue is primarily generated from the sale of diagnostic and procedural products used by obstetricians and gynecologists, including FemVue, FemCath, and FemCerv, which are utilized in uterine cavity assessment and related procedures. These products are sold predominantly in the United States through direct sales and distribution relationships.
The company’s development pipeline includes FemaSeed, an FDA-approved infertility treatment designed to improve intrauterine insemination outcomes, and FemaBloc, an investigational, non-surgical permanent contraception candidate currently in clinical development. Femasys Inc. controls the underlying intellectual property for its core technologies. The company does not report material manufacturing subsidiaries, and publicly available disclosures indicate reliance on third-party manufacturing and select commercial partners; specific long-term exclusive partnership arrangements are not consistently detailed, and data inconclusive based on available public sources.
Strategic Position & Investments
The strategic direction of Femasys Inc. is centered on expanding its commercial device revenue to support the clinical advancement of higher-value therapeutic assets. Growth initiatives focus on increasing adoption of its FDA-cleared diagnostic products within U.S. gynecology practices while progressing FemaBloc through regulatory pathways as a potential first-in-class, office-based permanent contraception alternative.
The company’s investment activity has primarily been internal, directed toward research and development, clinical trials, and intellectual property protection rather than external acquisitions. No material acquisitions or divestitures have been consistently reported in public filings. FemaBloc represents the most significant strategic investment and emerging technology platform, reflecting the company’s emphasis on combining mechanical delivery systems with pharmaceutical agents to create differentiated women’s health solutions.
Geographic Footprint
Femasys Inc. is headquartered in Atlanta, Georgia, and its operations are primarily concentrated in the United States. The majority of its commercial sales, clinical activities, and regulatory interactions occur domestically, consistent with its focus on FDA-regulated products and U.S.-based physician practices.
Internationally, the company reports limited market presence through select distribution arrangements for its diagnostic devices in Europe, Asia-Pacific, and Latin America, though these markets currently represent a smaller portion of overall activity. Public disclosures indicate international expansion is opportunistic rather than a primary strategic driver, and detailed country-level operational data is limited.
Leadership & Governance
Femasys Inc. was founded by Kathy Lee-Sepsick, who has played a central role in shaping the company’s clinical and strategic direction. Leadership emphasizes innovation in underserved areas of women’s health, with a stated focus on capital efficiency, clinical validation, and physician-centered product design. The company is governed by a board of directors with experience in medical devices, life sciences, and public company oversight.
Key members of the leadership team include:
- Kathy Lee-Sepsick – Chief Executive Officer & President
- David McKinley – Chief Financial Officer
- James A. Wood – Chief Operating Officer
- Anne Morrissey – Chief Regulatory Officer
The leadership team’s strategic vision centers on building long-term shareholder value by advancing proprietary women’s health technologies while maintaining a lean operational structure.